Ex-GSK Melanoma Therapy Secures EU Approval For Novartis
This article was originally published in Scrip
Novartis AG has been granted European approval for two products it picked up via a $20bn mega deal transaction with GlaxoSmithKline plc, a deal which closed in March this year.
You may also be interested in...
The EU's CHMP has granted a positive opinion for Novartis' combo of MEK inhibitor Mekinist and BRAF inhibitor Tafinlar for BRAF-positive non-small cell lung cancer patients.
Diversity in all forms is critical to innovation in health care, says AstraZeneca’s chief medical officer, Ann Taylor. In an exclusive interview, she talks about the company’s work in mentoring and education, and why tackling issues around diversity and inclusion must be driven by the C-suite alongside community initiatives.
A selection of articles you might have missed from October 2020, including exclusive interviews with industry leaders and a deeper dive into the Femtech market.